skatterbrainz t1_j3gr83g wrote on January 8, 2023 at 1:29 PM Reply to A randomized double-blind controlled trial found post-exposure prophylaxis with hydroxychloroquine (HCQ) was not advantageous for the prevention of COVID-19 in asymptomatic individuals with high risk for SARS-CoV-2 infection. The incidence of COVID-19 was similar in both the HCQ group and control. by glawgii Eventually AI and machines are going to replace pharmacists. The revenue advantages for pharma shareholders will outweigh any pushback. Permalink 0
skatterbrainz t1_j3gr83g wrote
Reply to A randomized double-blind controlled trial found post-exposure prophylaxis with hydroxychloroquine (HCQ) was not advantageous for the prevention of COVID-19 in asymptomatic individuals with high risk for SARS-CoV-2 infection. The incidence of COVID-19 was similar in both the HCQ group and control. by glawgii
Eventually AI and machines are going to replace pharmacists. The revenue advantages for pharma shareholders will outweigh any pushback.